Abstract: The present invention relates to an adjuvant ensemble in which two or more immunostimulatory substances for inducing the activation of various immune cells are combined, and to a novel concept of a kinetically acting adjuvant ensemble and use thereof, the treatment order and the time interval are adjusted to maximize the finally exhibited synergistic immunostimulatory response. The kinetically acting is characterized in that the second immunostimulatory substance responds to intrinsic factors (enzymes, redox potential, GSH, and pH) and extrinsic factors (redox, pH, temperature, photo/light, magnetism, ultrasound, and electrical response) in immune cells, and thus chemical binding at a binding site is cleaved, and the active site is exposed so that function is kinetically recovered, or two or more immunostimulatory substances are sequentially released from a carrier at regular time intervals, thus inducing immune activity.

Abstract: The present invention relates to an mRNA vaccine comprising an adjuvant of which an immune activating function is kinetically controlled and, more specifically, to an mRNA vaccine comprising an adjuvant characterized in that, after mRNA is transcribed into proteins, the activating function of the adjuvant is sequentially active. The present invention relates to a key technology for optimizing the time interval between mRNA antigen expression and immune activation in order to effectively control antigen expression and antigen immunogenicity, which conflict. In order to optimize an mRNA antigen expression amount and the active time of an adjuvant, the present invention provides a key technology, which kinetically controls the action of an immune activating substance to increase the expression amount and immunogenicity of an antigen at the same time, and thus remarkably increases the efficacy of an mRNA vaccine.

Abstract: The present invention relates to: a toll-like receptor 7 or 8 agonist-drug complex material in which a functional drug and a toll-like receptor 7 or 8 agonist are bonded by a chemical bond containing a cleavable site; and using the properties of the temporarily inactivated state, the side effects of the toll-like receptor 7 or 8 agonist can be reduced. In particular, the complex material is designed such that the immunostimulatory function of the toll-like receptor 7 or 8 agonist is inhibited due to the chemical bond, while the immunostimulatory function is recovered at an injection site or in a tumor microenvironment or target immune cells, thus exhibiting kinetic properties in which immunostimulatory efficacy can be controlled over time, and minimizing the induction of nonspecific immune responses.

Abstract: The present invention relates to: a lyophilized preparation of a pathogen cell wall skeleton, the preparation containing the pathogen cell wall skeleton as an active ingredient; various live-pathogen-mimetic nanoparticles produced by using the lyophilized preparation and antagonists of toll-like receptor 7 or 8 which can induce the efficacy of the live pathogen; a use thereof; and a production method thereof.

Abstract: The present invention relates to a cryogel scaffold capable of controlling the degree of degradation and a soft bio-integrated device in which a drug modulating an immunosuppressive action in solid tumor microenvironment is loaded in the scaffold.

Abstract: The present disclosure relates to a toll-like receptor 7/8 agonist-cholesterol complex comprising: a cholesterol; and a toll-like receptor 7/8 agonist, wherein the cholesterol is linked to an active site of the toll-like receptor 7/8 agonist.

Abstract: The present invention relates to a cryogel scaffold capable of controlling the degree of degradation and a soft bio-integrated device in which a drug modulating an immunosuppressive action in solid tumor microenvironment is loaded in the scaffold.

Abstract: The present invention relates to a nanoemulsion comprising an oil layer comprising imidazoquinoline-based toll-like receptor 7 or 8 agonist and oil, and a use thereof as an adjuvant and vaccine. According to the present invention, it is possible to provide a vaccine adjuvant in the form of a nanoemulsion that can dissolve an insoluble imidazoquinoline-based material in oil using a dispersion helper and disperse the oil solution easily and reproducibly in a water-soluble manner.

Abstract: The present invention relates to an antibacterial composition containing, as an active ingredient, adenylate kinase or adenosine kinase (ADK) protein derived from Mycobacterium tuberculosis, and a composition for preventing or treating infectious diseases. In addition, the present invention relates to a composition for preventing or treating sepsis or septic shock. Furthermore, the present invention relates to a method for preventing, improving or treating an infectious disease comprising administering the present antibacterial composition. The ADK protein derived from Mycobacterium tuberculosis according to the present invention has excellent antibacterial activity selectively against gram-negative bacteria, and thus can be favorably used as an antibacterial composition against gram-negative bacteria or for the prevention or treatment of infectious diseases caused by gram-negative bacteria.

Abstract: The present invention relates to a multi-domain vesicle comprising an immunosuppressive factor control material, a production method of the multi-domain vesicle and an immunomodulatory composition comprising the multi-domain vesicle. According to one aspect of the present invention, the multi-domain vesicle comprises: at least two liposomes making contact and connected with each other, and a multi-domain vesicle outer wall surrounding the at least two liposomes.

Abstract: The present invention relates to a multi-domain vesicle comprising an immunostimulatory material, a production method of the multi-domain vesicle and an immunomodulatory composition comprising the multi-domain vesicle. According to one aspect of the present invention, the multi-domain vesicle comprises: at least two liposomes making contact and connected with each other, and a multi-domain vesicle outer wall surrounding the at least two liposomes.

Abstract: The present invention relates to an antibacterial composition containing, as an active ingredient, adenylate kinase or adenosine kinase (ADK) protein derived from Mycobacterium tuberculosis, and a composition for preventing or treating infectious diseases. In addition, the present invention relates to a composition for preventing or treating sepsis or septic shock. Furthermore, the present invention relates to a method for preventing, improving or treating an infectious disease comprising administering the present antibacterial composition. The ADK protein derived from Mycobacterium tuberculosis according to the present invention has excellent antibacterial activity selectively against gram-negative bacteria, and thus can be favorably used as an antibacterial composition against gram-negative bacteria or for the prevention or treatment of infectious diseases caused by gram-negative bacteria.

Abstract: A thermosensitive ionic composite having a multistage phase transition characteristic, a method for preparing the thermosensitive ionic composite, and a biodegradable composition containing the thermosensitive ionic composite are provided.

Abstract: The present invention relates to an optical imaging probe for detecting a sentinel lymph node, which contains a complex of poly-gamma-glutamic acid and an optical imaging dye, and more particularly to an optical imaging probe for detecting a sentinel lymph node, which contains a poly-gamma-glutamic acid/optical imaging dye complex that, when injected subcutaneously in vivo, remains in the sentinel lymph node for a relatively long period of time and has a low tendency to migrate to other lymph nodes. The present invention provides a poly-gamma-glutamic acid/fluorescent dye complex, which contains no radiopharmaceutical and is harmless to the human body. The use of the poly-gamma-glutamic acid/fluorescent dye complex makes it possible to accurately detect the position of a sentinel lymph node in real time without concerns about radioactive contamination.

Abstract: The present invention relates to nanomicelles composed of a complex of a lipophilic compound and a poly-gamma-glutamic acid wherein a portion of carboxyl groups are substituted with an amine group, and more particularly, to nanomicelles composed of a complex of a lipophilic compound and a poly-gamma-glutamic acid wherein a portion of carboxyl groups are substituted with an amine group, a preparation method thereof, and a drug delivery system employing the mucous membrane-adhesive property of the nanomicelles. According to the present invention, the nanomicelle drug delivery system based on poly-gamma-glutamic acid that is a natural biopolymer can be used for the delivery of a drug to mucous membranes to thereby increase the in vivo stability and effectiveness of the drug.

Abstract: The present invention relates to a composition for dispersing or hydrating mucus, which comprises poly-gamma-glutamic acid, a biocompatible natural polymer, and more particularly, to a composition for treating mucus hypersecretory disease, which comprises poly-gamma-glutamic acid or poly-gamma-glutamic acid nanogels. The composition according to the present invention is effective in treating mucus-related diseases by effectively dispersing and hydrating mucus which is excessively secreted in vivo and highly sticky.

Abstract: A composition for drug delivery based on a biocompatible anionic polymer and a producing method thereof are provided.

Abstract: The present invention relates to an adjuvant composition containing poly-gamma-glutamic acid-chitosan nanoparticles and a vaccine composition containing the adjuvant composition, and more particularly to an adjuvant composition containing nanoparticles prepared by ionic bonding between poly-gamma-glutamic acid having ensured safety and chitosan, and a vaccine composition containing the poly-gamma-glutamic acid-chitosan nanoparticles and an antigen. The adjuvant containing the poly-gamma-glutamic acid-chitosan nanoparticles has little or no toxicity and side effects and is added to human or animal vaccines for the prevention and treatment of viral and bacterial infections and cancers to increase the production of antibodies.

Abstract: A thermosensitive ionic composite having a multistage phase transition characteristic, a method for preparing the thermosensitive ionic composite, and a biodegradable composition containing the thermosensitive ionic composite are provided.

Abstract: The present invention relates to a nano-composite containing anionic and cationic polymers and a method for preparing thereof, and more particularly to a poly-gamma-glutamic acid (?-PGA)/chitosan/manganese iron oxide nanoparticle composite prepared by encapsulating iron oxide-based nanoparticles in a ?-PGA/chitosan polymer composite using the ionic self-assembly properties of poly-gamma-glutamic acid (?-PGA) and chitosan, which are biocompatible polymer materials, and to a method for preparing thereof. The present invention provides a magnetic resonance imaging nano-contrast agent based on a nanoparticle composite including iron oxide-based nanoparticles encapsulated in a self-assembled composite of anionic poly-gamma-glutamic acid (?PGA) and cationic chitosan.